Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

Rivaroxaban monotherapy safe, effective in AF, stable CAD patients

14 Nov 2019

In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.

AFIRE included 2,236 adult AF patients in Japan who had undergone percutaneous coronary intervention (PCI) or coronary-artery bypass grafting (CABG) >1 year earlier or who had angiographically confirmed CAD not requiring revascularization.

The patients were randomly assigned to receive rivaroxaban alone (n=1,118) or in combination with a single antiplatelet agent (n=1,118), but only 1,107 and 1,108 patients, respectively, were included in the modified intention-to-treat population (mean age, 74 years; 79 percent male).

Due to increased mortality in the combination group, the trial was terminated prematurely. This said, the effect of rivaroxaban monotherapy on the primary efficacy endpoint a composite of stroke, systemic embolism, myocardial infarction, unstable angina requiring revascularization or death from any cause proved noninferior to that of the combination (event rate, 4.14 percent vs 5.75 percent per patient-year; hazard ratio [HR], 0.72, 95 percent confidence interval [CI], 0.55–0.95; p-noninferiority<0.001).

In terms of safety, the monotherapy showed superiority, with the rate of major bleeding being 1.62 per patient year as opposed to 2.76 percent per patient-year with the combination (HR, 0.59, 95 percent CI, 0.39–0.89; p-superiority=0.01).

The findings must be interpreted in light of several limitations, according to researchers, pointing out that the early termination of the trial may overestimate the efficacy data. Thee researchers acknowledged that the benefit of rivaroxaban monotherapy on the rate of ischaemic events and death from any cause was unexpected and might be due to the play of chance.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]